Recent Finacing
Recent Raise
STRM.BIO develops a megakaryocyte-derived vesicle platform that enables non-viral, in vivo delivery of genetic medicines to bone marrow cells.
Focus Areas
Recent Investors
Total Raised
Funding round
See the team members at STRM.BIO.
